# Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

> **NCT03026933** · PHASE3 · COMPLETED · sponsor: **Kuhnil Pharmaceutical Co., Ltd.** · enrollment: 215 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** KI1107 4 Capsules, QD
- **DRUG:** Rosuvastatin Calcium 20 MG, QD

## Key facts

- **NCT ID:** NCT03026933
- **Lead sponsor:** Kuhnil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026933, "Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03026933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*